Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients

被引：0
|
作者：
Desmedt, C.
Andre, F.
Azambuja, E.
Haibe-Kains, B.
Larsimont, D.
D'Hondt, V.
Di Leo, A.
Piccart, M.
Pusztai, L.
Sotiriou, C.
机构：
[1] Jules Bordet Inst, Brussels, Belgium
[2] Inst Gustave Roussy, Villejuif, France
[3] Prato Hosp, Prato, Italy
[4] MD Anderson, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10564
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
    Marin Alcala, M.
    Llort Pursals, G.
    Del Riego Ferrari, J. H.
    Giner, J.
    Andreu Navarro, F. X.
    Medina, S.
    Aparicio, O.
    Dalmau Portulas, E.
    Ribera Fernandez, P.
    Oliveres, H.
    Martinez Vila, C.
    Cabrera Romero, J. M.
    Segui Palmer, M. A.
    Fernandez Morales, L. A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Intratumor expression of splice variants of estrogen receptor (ER)-β and response to neoadjuvant toremifene (TOR) in elderly patients with breast cancer (BC)
    Celio, L.
    Cappelletti, V.
    Denaro, A.
    Martinetti, A.
    Longarini, R.
    Giovanazzi, R.
    Greco, M.
    Daidone, M. G.
    Bajetta, E.
    ANNALS OF ONCOLOGY, 2005, 16 : 40 - 40
  • [23] Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial
    Ana Julia Aguiar Freitas
    Caroline Rocha Nunes
    Max Senna Mano
    Rhafaela Lima Causin
    Iara Viana Vidigal Santana
    Marco Antonio de Oliveira
    Stéphanie Calfa
    Henrique César Santejo Silveira
    Cristiano de Pádua Souza
    Márcia Maria Chiquitelli Marques
    Scientific Reports, 13
  • [24] Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial
    Aguiar Freitas, Ana Julia
    Nunes, Caroline Rocha
    Mano, Max Senna
    Causin, Rhafaela Lima
    Vidigal Santana, Iara Viana
    de Oliveira, Marco Antonio
    Calfa, Stephanie
    Santejo Silveira, Henrique Cesar
    Souza, Cristiano de Padua
    Chiquitelli Marques, Marcia Maria
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [25] HMGA2 expression and response to anthracycline-based preoperative chemotherapy in patients with operable breast cancer
    Puglisi, F.
    Ermacora, P.
    Driol, P.
    Masolini, P.
    Alessi, B.
    Pisa, F. E.
    Pandolfi, M.
    Mansutti, M.
    Giancotti, V.
    Di Loreto, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] The Predictive Value of P53 Expression to Anthracycline-Based Neo-Adjuvant Therapy in Triple Negative Breast Cancer Patients
    Yang, J. T.
    Liu, C. Z.
    Dooley, W.
    Squires, R.
    Jett, E.
    Parker, J.
    LABORATORY INVESTIGATION, 2012, 92 : 74A - 75A
  • [27] The Predictive Value of P53 Expression to Anthracycline-Based Neo-Adjuvant Therapy in Triple Negative Breast Cancer Patients
    Yang, J. T.
    Liu, C. Z.
    Dooley, W.
    Squires, R.
    Jett, E.
    Parker, J.
    MODERN PATHOLOGY, 2012, 25 : 74A - 75A
  • [28] CAN ER/PR AND HER2 RECEPTOR STATUS PREDICT COMPLETE PATHOLOGICAL RESPONSE AFTER NEO-ADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER?
    Sircar, T.
    Athwal, R.
    Brown, H.
    Dea, D.
    Hoar, F.
    EJC SUPPLEMENTS, 2010, 8 (06): : 11 - 11
  • [29] Comprehensive profiling of cancer associated cells in the blood of breast cancer patients to predict pathological complete response.
    Pore, Adity A.
    Dhanasekara, Chathurika S.
    Bin Navaid, Hunaiz
    Vanapalli, Siva A.
    Rahman, Rakhshanda Layeequr
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] A multifactorial ‘consensus signature’ by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer
    Turner N.
    Forcato M.
    Nuzzo S.
    Malorni L.
    Bicciato S.
    Di Leo A.
    npj Breast Cancer, 1 (1)
12345